13065 More moderate levels of disease severity at baseline related to achievement of treatment targets with apremilast: Results from a pooled analysis

Mark Lebwohl; Ulrich Mrowietz; Alan Menter; Christopher Em Griffiths; Jerry Bagel; Natalie Núnez Gómez; Rui Shi; Rebecca Shi; B. Guérette; Eugenia Levi; Kristian Reich

doi:10.1016/j.jaad.2020.06.549

Back

Shared by

Christopher Em Griffiths

13065 More moderate levels of disease severity at baseline related to achievement of treatment targets with apremilast: Results from a pooled analysis

Article 2020 en

Authors

ML
Mark Lebwohl
UM
Ulrich Mrowietz
AM
Alan Menter

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis

Kristian Reich, Ulrich Mrowietz, Alan Menter, Christopher Em Griffiths, Jerry Bagel, Bruce Strober, Natalie Núnez Gómez, Rebecca Shi, B. Guérette, Mark Lebwohl

Article2007

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year

Phoebe Rich, Christopher Em Griffiths, Kristian Reich, Frank O. Nestlé, Richard K. Scher, Shu Li, Stephen Xu, Ming-Chun Hsu, Cynthia Guzzo

Article2014

Rice consumption and risk of cardiovascular disease: results from a pooled analysis of 3 U.S. cohorts

Isao Muraki, Hongyu Wu, Fumiaki Imamura, Francine Laden, Eric B. Rimm, Frank B Hu, Walter C. Willett, Qi Sun

Article2019

PSS6 COMPARISON OF TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE

David Kaplan, Benjamin S.‐Y. Ung, Corey Pelletier, Chuka Udeze, M. Tian

Article2019

PMS37 RATES OF REAL-WORLD TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE

David Kaplan, Benjamin S.‐Y. Ung, Corey Pelletier, Chuka Udeze, M. Tian